Effect of glucagon, dibutyryl adenosine 3',5'-cyclic monophosphate and phosphodiesterase inhibitors on rat liver phosphorylase activity and adenosine 3',5'-cyclic monophosphate levels.
D000818:Animals; D003994:Bucladesine / Q000494:pharmacology*; D002264:Carboxylic Acids / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D005934:Glucagon / Q000494:pharmacology*; D006834:Hydrazines / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D008099:Liver / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D010208:Papaverine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D006005:Phosphorylases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011720:Pyrazoles / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D013806:Theophylline / Q000494:pharmacology; D013997:Time Factors
D002264:Carboxylic Acids; D006834:Hydrazines; D010726:Phosphodiesterase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D003994:Bucladesine; D005934:Glucagon; D013806:Theophylline; D010208:Papaverine; D000242:Cyclic AMP; D006005:Phosphorylases; D010727:Phosphoric Diester Hydrolases